02595 勁方醫藥－Ｂ
GENFLEET-B
GENFLEET-B
| Listing Date | 2025/09/19 |
| Listing Price | 20.390 |
Subscription Result
- Subscription Rate2,662.79x
- Guarantee One Lot Size4500 lot
- One Lot Success Rate0.08%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
GenFleet Therapeutics (Shanghai) was founded in 2017, it is a biopharmaceutical company focused on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases.
--
As of August 18, 2025, the Group had established a product pipeline consisting of eight product candidates with five under clinical development, including two Core Products — GFH925 and GFH375. The Group’s revenue was derived from its collaboration with Innovent regarding its Core Product GFH925, Verastem regarding its Core Product GFH375, and SELLAS regarding GFH009.
--
GFH925 (fulzerasib, marketed under the brand name Dupert), an in-house discovered new drug, has been approved for commercialization in China for the treatment of advanced non-small cell lung cancer, and it was China’s first and globally the third approved selective inhibitor of Kirsten rat sarcoma G12C.
--
GFH375 is an orally bioavailable small molecule inhibitor of KRAS G12D. The Group have initiated the Phase II part of a Phase I/II clinical trial in patients with advanced solid tumors harboring the KRAS G12D mutation in China.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 89.24M H shares |
| No. of International Offer Shares | 81.48M H shares |
| No. of HK Offer Shares | 7.76M H shares |
| Offer Price | $20.39 |
| Stock Code | 2595 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | CLSA Limited, BOCOM International Securities Limited, Fosun International Securities Limited, ABCI Securities Company Limited, China Renaissance Securities (Hong Kong) Limited, CCB International Capital Limited, GF Securities (Hong Kong) Brokerage Limited |
TIME TABLE
| Application Period | Sep 11 (Thu) - noon, Sep 16 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Sep 18 (Thu) |
| Result Announcement Date | On or before Sep 18 (Thu) |
| Result Announcement Date | On or before Sep 19 (Fri) |
| Dealings in Shares commence on | Sep 19, 2025. (Fri) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $20.39 |
| Capitalization | 7.04B |
| NAV / share ($) | $5.06 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 20.39, the net proceeds raised would be HKD 1.44B, of which |
| 33% : Fund the clinical development of our Core Product GFH925 |
| 38% : Fund the clinical development of our Core Product GFH375 |
| 19% : Fund the further development of our other candidates in pipeline |
| 10% : Working capital |
IPO NEWS
| 19/09/2025 16:08 |
| {New Stock}GENFLEET-B(02595) ends up 106.47% at HK$42.1 |
| 19/09/2025 09:20 |
| {New Stock}GENFLEET-B(02595) opens up 115.79% at HK$44 |
| 18/09/2025 18:35 |
| {New Stock}GENFLEET-B(02595) ends up 102.16% on grey market |
| 18/09/2025 16:20 |
| {New Stock}GENFLEET-B up 110.4% at HK$42.9 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).